+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy of SL-325 in adults with moderate to severely active Crohns disease. This phase 2 randomized, double-blind, placebo-controlled study aims to assess whether SL-325 can improve disease activity in participants who have not responded well to certain prior Crohns disease treatments. The trial is sponsored by Shattuck Labs, Inc. and involves multiple doses of the study drug. Participants will receive SL-325 or a placebo intravenously during the study. The study includes a screening period lasting up to 6 weeks, followed by a 12-week induction treatment phase, a 38-week maintenance phase, and a 52-week long-term extension period. After these treatment phases, there is a 10-week follow-up period to monitor participants. During the trial, participants will undergo various assessments to monitor their disease status and safety. The main outcome measured is the proportion of participants achieving an endoscopic response at Week 12. Additional outcomes include clinical remission rates and monitoring of treatment-emergent adverse events. The total participation may last over two years, including all study periods and follow-up.

Age: 18Years - 80YearsAll GendersPhase 2
20 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of LY4268989 compared to a placebo in adults with moderately to severely active ulcerative colitis UC. The study involves participants aged 18 to 80 who have had UC for at least three months and have active symptoms confirmed by specific scoring methods. This Phase 2 clinical trial is sponsored by Eli Lilly and Company and focuses on treatment effects over a long period. Participants will receive oral doses of LY4268989 or a matching placebo in a randomized, double-blind design. The study includes two experimental dose groups of LY4268989 and one placebo group. Treatment and evaluation will continue for up to approximately 108 weeks, excluding the screening period. During the trial, participants will be regularly assessed for clinical remission and response using the Modified Mayo Score at weeks 10 and 52. Researchers will monitor symptomatic responses and drug levels in the blood up to week 52. Safety and effectiveness data will be collected throughout the study, with the overall duration lasting up to about two years.

Age: 18Years - 80YearsAll GendersPhase 2
258 locations